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ABSTRACT
TEM-1 and TEMpUC19 b-lactamases can gain
activity against ceftazidime and other expanded-
spectrum cephalosporins via point mutation. The
frequency of emergent resistance to ceftazidime at
4 · MIC was elevated ‡ 250-fold in hyper-muta-
ble, MutS-deficient Escherichia coli harbouring
these b-lactamase genes on high- or low-copy
plasmids. Moreover, although ceftazidime-resist-
ant mutants, or those with reduced susceptibility,
were selected in both the wild-type and mutS
hosts, many more mutants in the mutS host
showed ceftazidimase-type extended-spectrum
b-lactamase (ESBL) activity. This correlated with
a G–A point mutation at position 484 in the
blaTEM-1 and blaTEM-pUC19 genes, conferring the
Arg164His amino-acid substitution found in
the TEM-29 ESBL. Non-ESBL mutants lacked
changes in blaTEM.
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An elevated mutation frequency in wild popula-
tions of Escherichia coli is associated most often
with lesions in the DNA repair pathway gene
mutS [1], which is responsible for post-replicative
DNA repair. Such lesions can modulate the
chromosomal mutation frequency by up to 1000-
fold [2], and it has been suggested that the
emergence of resistance from plasmid-borne
genes should also be increased [3]. This may be
relevant to the evolution of extended-spectrum [4]
and inhibitor-resistant variants of TEM and SHV
b-lactamases. Although CTX-M-type extended-
spectrum b-lactamases (ESBLs) are now more
prevalent than TEM- and SHV-ESBLs in Asia and
Europe [5,6], the latter remain the main ESBL
types in the USA and are common elsewhere [7],
with over 190 variants described to date (http://
www.lahey.org/studies/webt.htm). Amino-acid
substitutions at a limited number of residues
can critically extend the substrate range, with
substitutions at positions 104, 238 and 164 being
particularly important in the TEM family [8].
A few studies have examined the role of
mutators in the evolution of ESBL activity [9,10]
but, to date, TEM-ESBL development has been
studied only in a dnaQ E. coli mutator strain [10].
In contrast to mutS [1], no wild-type isolates with
lesions in dnaQ have been described. The present
study examined the effect of mutS-mediated
hyper-mutability on the development of ceftazid-
imase activity in TEM-1-type penicillinases in
wild-type and MutS-negative E. coli strains
carrying a blaTEM gene on either (1) a low-copy-
number plasmid, as is the case for most
TEM-encoding R plasmids, or (2) high-copy-
number pUC19-type plasmids [11].
The pUC19-encoded b-lactamase TEMpUC19
differs from classic TEM-1 by two amino-acid
substitutions, Val84Ile and Ala184Val, on the
515-bp XmnI and BsrFI fragment of pUC19. For
part of this study, this fragment was excised
and replaced by the corresponding fragment of
TEM-1 from plasmid pBR322. Transformants
were selected on nutrient agar containing ampi-
cillin 100 mg ⁄L and were checked by sequen-
cing the blaTEM gene on both strands using a CEQ
8000 DNA sequencer (Beckman-Coulter, High
Wycombe, UK). The resulting plasmid was desig-
nated pTEM-1.
High-copy-number plasmids pUC19 and
pTEM-1, and low-copy-number plasmid pBR322,
were each electroporated into electrocompetent
cells of strains 1411 (wild-type) and 1413 (mutS-
negative) [12]. Transformants were selected on
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nutrient agar containing ampicillin 100 mg ⁄L,
and the blaTEM genes were sequenced. MICs were
determined by Etest (AB Biodisk, Solna, Sweden)
on IsoSensitest agar or by agar dilution on
IsoSensitest agar [13]. None of these plasmids
caused any significant increase in the MIC of
ceftazidime.
Selection of mutants was performed on nutrient
agar containing ceftazidime at 4 · MIC in tripli-
cate experiments from three independent cul-
tures. Inocula comprised 109 CFU from overnight
nutrient broth cultures grown from single colon-
ies. Plates were incubated aerobically at 37C for
18 h, after which the colonies were counted.
Mutants resistant to ceftazidime at 4 · MIC were
obtained from the mutS strain harbouring the
high-copy-number plasmids pTEM-1 or pUC19
c. 250-fold and > 300-fold more frequently than
from the corresponding wild-type strain carrying
these same plasmids (Table 1), but the emergence
of ceftazidime resistance was at an order of
magnitude lower in both hosts harbouring
pBR322, as compared with the higher-copy-
number vectors. Nevertheless, a differential of
c. 300-fold was still observed between transform-
ants of the wild-type and mutS strains (Table 1).
Randomly selected mutants from separate
experiments with each of the six host strain–
plasmid combinations were chosen in roughly
equal proportions for MIC determinations
(Table 2). In the mutS host, 17 pTEM-1, 15
pUC19 and 18 pBR322 mutants had ceftazidime
MICs of 2–16 mg ⁄L (pUC19 and pBR322 mutants)
and 2–64 mg ⁄L (pTEM-1 mutants) (Table 2). All
50 mutants had decreased susceptibility to cefep-
ime, and showed ‡ 8-fold potentiation of ceftaz-
idime in the presence of clavulanate (Table 2),
suggesting the development of ESBL activity.
All of the mutants selected from transformants
of the non-hyper-mutable strain containing pUC19
or pTEM-1 (n = 28) had decreased susceptibility to
ceftazidime, but remained susceptible to £ 1 mg ⁄L.
Moreover, there was < 8-fold potentiation of
ceftazidime by clavulanate for these mutants,
suggesting that they lacked ESBL activity. Among
13 mutants of the wild-type host (1411) containing
the lower-copy-number plasmid pBR322, four
had ceftazidime MICs of 4 mg ⁄L, and two of
these showed > 8-fold potentiation of ceftazidime
by clavulanate, implying ESBL activity.
From each of the six host–plasmid combina-
tions, 30 ceftazidime-selected mutants of pUC19,
pTEM-1 and pBR322 blaTEM genes were seq-
uenced. The latter 30 comprised 15 wild-type
and 15 mutS variants; two of the former and 12 of
the latter had ESBL phenotypes. All 12 mutants
with ESBL phenotypes (three, five and four
derived from pUC19, pTEM-1 and pBR322,
respectively) harboured TEM genes carrying a
G–A point mutation at nucleotide 484 of the
blaTEM open reading frame, resulting in an
Arg164His amino-acid substitution. This change
is known to confer ESBL activity [14], changing
TEM-1 into TEM-29. Both wild-type (1411) mu-
tants with an ESBL phenotype harboured pBR322
that encoded TEM-29. Upon re-transformation
into fresh host cells, plasmids encoding TEM-29
conferred identical MIC profiles to those of the
original mutants, indicating that the observed
resistances were mediated by the plasmid alone.
The ESBL-negative mutants selected from
strain 1411 harbouring pTEM-1, pUC19 or
pBR322 showed up to eight-fold reductions in
ceftazidime susceptibility, although MICs did not
exceed the BSAC resistance breakpoint of 2 mg ⁄L
[13] (Table 2). No increase in AmpC b-lactamase
activity was detected with a cloxacillin potentia-
tion test comparing zones around 30-lg cefotax-
ime and 30-lg ceftazidime disks (Oxoid,
Basingstoke, UK) on IsoSensitest agar with and
without cloxacillin 100 mg ⁄L. However, these
variants had up to eight-fold decreased suscepti-
bility to cefoxitin, tetracycline and ciprofloxacin,
as well as decreased OmpF expression following
SDS-PAGE analysis (data not shown). The dis-
parity in the number of ESBL and OmpF mutants
selected among the MutS and wild-type hosts,
and the lack of mutants hyper-expressing the
Table 1. Mean frequencies of mutation to ceftazidime
resistance at 4 · starting MIC for wild-type and hyper-
mutable, mutS-negative Escherichia coli with and without
pUC19, pTEM-1 or pBR322
Strain
Mean mutation
frequency at 4 · MICa
Ceftazidime
MIC (mg ⁄L)
1411 2.11 ± 0.34 · 10)9 0.03
1413 3.90 ± 0.45 · 10)7 0.06
1411 ⁄pUC19 6.70 ± 0.70 · 10)8 0.25
1413 ⁄pUC19 3.00 ± 0.35 · 10)5 0.25
1411 ⁄pTEM-1 4.14 ± 0.84 · 10)8 0.25
1413 ⁄pTEM-1 1.18 ± 0.08 · 10)5 0.25
1411 ⁄pBR322 2.07 ± 0.71 · 10)8 0.25
1413 ⁄pBR322 6.03 ± 0.23 · 10)6 0.25
aMutation frequencies are arithmetic means from three independent experiments,
each performed in triplicate, calculated as a fraction of the total number of viable
bacteria, as determined by serial dilution and plate counts on nutrient agar.
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chromosomal AmpC b-lactamase, could be
caused by differences in the fitness cost of each
type of mutation.
The mutation frequency for resistance to ceftzi-
dime at 4 · MIC and 1 mg ⁄L for the plasmid-free
wild-type (1411) and mutS (1413) strains was
180-fold higher in the mutS host at 4 · MIC of
ceftazidime (Table 1). At 1 mg ⁄L, it was only
possible to select mutants from the mutS strain.
Elevated MICs of ceftazidime, cefoxitin, tetra-
cycline and ciprofloxacin were observed for the
mutants (Table 2), suggesting changes to cell
impermeability or efflux systems.
In summary, these experiments indicate the
potential of hyper-mutators to extend the hydro-
lysis spectra of TEM b-lactamases encoded by
high- and low-copy-number plasmids. An
Arg164His change was detected in the ESBL
mutants generated from pUC19, pTEM-1 and
pBR322. In the case of pTEM-1 and pBR322, this
changed TEM-1 into the TEM-29 ESBL [15]. The
same substitution is present in c. 10% of the
different TEM-ESBL variants described to date
(http://www.lahey.org/studies/webt.htm), and
TEM-29 may have been a progenitor for the
development of further variants, perhaps facilita-
ted by mutator hosts. In contrast, the wild-type
strain with TEM-encoding plasmids yielded
mostly mutants with changes in the host chro-
mosome rather than blaTEM.
The observation of mutator strains among
natural E. coli populations [1], and their increased
prevalence among ESBL-producing urinary tract
isolates [16], raises the possibility that TEM-ESBLs
may also evolve in mutator strains. This may
explain the frequent association between ESBL
activity and other resistances contingent upon
mutation, e.g., that to fluoroquinolones [17].
ACKNOWLEDGEMENTS
The authors wish to thank R. Lloyd for the gift of E. coli strains,
B. Bridges for discussions, and the UK Department of Health
for financial support (grant no. 91 of the Resistance to
Antibiotics and other Antimicrobial Agents Research Pro-
gramme). This work was presented, in part, at the 44th
Interscience Conference on Antimicrobial Agents and Chemo-
therapy (Washington, DC, 2004) and the 15th European
Congress of Clinical Microbiology and Infectious Diseases
(Copenhagen, 2005).
REFERENCES
1. LeClerc JE, Li B, Payne WL, Cebula TA. High mutation
frequencies among Escherichia coli and Salmonella patho-
gens. Science 1996; 274: 1208–1211.
Table 2. MICs (mg ⁄L) for wild-type and hyper-mutable mutS Escherichia coli strains, with and without pUC19, pTEM-1
and pBR322, together with their selected mutants
Strain ⁄mutant Plasmid AZT CTX CAZ CAZC CPM FOX IPM CIP TET CHL
1411 (wild-type parent) – £ 0.125 £ 0.125 0.03 £ 0.06 £ 0.125 4 0.25 £ 0.125 0.5 4
1411 ⁄pUC19 pUC19 £ 0.125 £ 0.125 0.25 £ 0.06 £ 0.125 4 0.25 0.25 0.5 4
1411 ⁄pTEM-1 pTEM-1 £ 0.125 £ 0.125 0.25 £ 0.06 £ 0.125 2 0.25 £ 0.125 0.5 4
1411 ⁄pBR322 pBR322 0.25 £ 0.125 0.25 0.125 £ 0.125 8 0.25 £ 0.125 > 32 4
CAZ-selected mutants
1411 ⁄pUC19, n = 14 pUC19 £ 0.125–0.5 £ 0.125 0.5–1 0.25–0.5 £ 0.125–0.25 8–16 0.25–1 0.5–1 1–4 4–8
1411 ⁄pTEM-1, n = 14 pTEM-1 0.5–1 £ 0.125 1–2 0.25–1 0.5 8–16 0.25–0.5 0.25–0.5 2–4 4–8
1411 ⁄pBR322, n = 13 pBR322 £ 0.125–0.5 £ 0.125 0.25–4 0.06–0.5 £ 0.125–0.5 2–8 0.25–1 £ 0.125–0.25 > 32 4–8
ESBL-negative
e.g., 1411 ⁄pUC19 m1 pUC19 £ 0.125 £ 0.125 1 0.25 £ 0.125 8 0.5 1 2 4
e.g., 1411 ⁄pUC19 m3 pUC19 0.25 £ 0.125 0.5 0.25 £ 0.125 16 0.25 0.5 0.5 4
ESBL-positive
e.g., 1411 ⁄pBR322 m2 pBR322 0.25 £ 0.125 4 0.060 0.5 4 0.5 £ 0.125 > 32 4
1413 (mutS parent) – £ 0.125 £ 0.125 0.06 0.125 £ 0.125 8 0.5 0.25 1 4
1413 ⁄pUC19 pUC19 £ 0.125 £ 0.125 0.5 0.125 £ 0.125 4 0.25 0.25 1 4
1413 ⁄pTEM-1 pTEM-1 £ 0.125 £ 0.125 0.25 0.125 £ 0.125 4 0.25 0.25 1 4
1413 ⁄pBR322 pBR322 £ 0.125 £ 0.125 0.25 0.125 £ 0.125 8 1 0.25 > 32 4
CAZ-selected mutants
1413 ⁄pUC19, n = 15 pUC19 0.25–2 £ 0.125–0.25 2–64 0.25–1 0.25–4 4–32 0.25–1 0.25–0.5 2–4 4–8
1413 ⁄pTEM-1, n = 17 pTEM-1 £ 0.125–0.5 £ 0.125 2–16 0.125–0.25 £ 0.125–0.5 2–8 £ 0.125–0.5 0.25–0.5 1–4 4–8
1413 ⁄pBR322 n = 18 pBR322 £ 0.125–0.5 £ 0.125 0.5–8 0.125–0.25 £ 0.125–0.5 4–8 0.25–1 0.25 > 32 4–8
ESBL-negative
e.g., 1413 ⁄pUC19 m11 pUC19 0.5 £ 0.125 2 1 1 8 0.5 0.5 4 8
e.g., 1413 ⁄pBR322 m111 pBR322 £ 0.125 £ 0.125 2 0.25 £ 0.125 8 1 0.25 > 32 4
ESBL-positive
e.g., 1413 ⁄pUC19 m13 pUC19 1 £ 0.125 16 0.25 1 4 0.5 0.5 2 8
e.g., 1413 ⁄pUC19 m14 pUC19 1 £ 0.125 8 0.25 1 4 0.5 0.5 2 4
e.g., 1413 ⁄pTEM-1 m18 pTEM-1 0.5 £ 0.125 16 0.25 0.25 4 0.25 0.25 2 4
e.g., 1413 ⁄pBR322 m1 pBR322 0.5 £ 0.125 8 0.25 0.5 4 0.5 0.25 > 32 4
AZT, aztreonam; CTX, cefotaxime; CAZ, ceftazidime; CAZC, CAZ plus clavulanate 4 mg ⁄L; CPM, cefepime; FOX, cefoxitin; CIP, ciprofloxacin; IMP, imipenem; TET,
tetracycline; CHL, chloramphenicol.
802 Clinical Microbiology and Infection, Volume 12 Number 8, August 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 793–821
2. Miller JH. Mutators in Escherichia coli. Mutat Res 1998; 409:
99–106.
3. Chopra I, O’Neill AJ, Miller K. The role of mutators in the
emergence of antibiotic-resistant bacteria. Drug Resist
Update 2003; 6: 137–145.
4. Bush K. New beta-lactamases in gram-negative bacteria:
diversity and impact on the selection of antimicrobial
therapy. Clin Infect Dis 2001; 32: 1085–1089.
5. Bonnet R. Growing group of extended-spectrum b-lacta-
mases: the CTX-M enzymes. Antimicrob Agents Chemother
2004; 48: 1–14.
6. Woodford N, Ward ME, Kaufmann ME et al. Community
and hospital spread of Escherichia coli producing CTX-M
extended-spectrum beta-lactamases in the UK. J Antimicrob
Chemother 2004; 54: 735–743.
7. Paterson DL, Hujer KM, Hujer AM et al. Extended-spec-
trum beta-lactamases in Klebsiella pneumoniae bloodstream
isolates from seven countries: dominance and widespread
prevalence of SHV- and CTX-M-type beta-lactamases.
Antimicrob Agents Chemother 2003; 47: 3554–3560.
8. Bradford PA. Extended-spectrum beta-lactamases in the
21st century: characterization, epidemiology, and detec-
tion of this important resistance threat. Clin Microbiol Rev
2001; 14: 933–951.
9. Galan JC, Morosini MI, Baquero MR, Reig M, Baquero F.
Haemophilus influenzae bla (ROB-1) mutations in hyper-
mutagenic DampC Escherichia coli conferring resistance to
cefotaxime and b-lactamase inhibitors and increased sus-
ceptibility to cefaclor. Antimicrob Agents Chemother 2003;
47: 2551–2557.
10. Orencia MC, Yoon JS, Ness JE, Stemmer WP, Stevens RC.
Predicting the emergence of antibiotic resistance by
directed evolution and structural analysis. Nat Struct Biol
2001; 8: 238–242.
11. Yanisch-Perron C, Vieira J, Messing J. Improved M13
phage cloning vectors and host strains: nucleotide se-
quences of the M13mp18 and pUC19 vectors. Gene 1985;
33: 103–119.
12. Miller K, O’Neill AJ, Chopra I. Response of Escherichia coli
hypermutators to selection pressure with antimicrobial
agents from different classes. J Antimicrob Chemother 2002;
49: 925–934.
13. Andrews JM. BSAC standardized disc susceptibility test-
ing method (version 3). J Antimicrob Chemother 2004; 53:
713–728.
14. Vakulenko SB, Taibi-Tronche P, Toth M et al. Effects on
substrate profile by mutational substitutions at positions
164 and 179 of the class A TEMpUC19 beta-lactamase from
Escherichia coli. J Biol Chem 1999; 274: 23052–23060.
15. Raquet X, Lamotte-Brasseur J, Fonze E et al. TEM beta-
lactamase mutants hydrolysing third-generation cephalo-
sporins. A kinetic and molecular modelling analysis. J Mol
Biol 1994; 244: 625–639.
16. Baquero MR, Galan JC, del Carmen TM et al. Increased
mutation frequencies in Escherichia coli isolates harboring
extended-spectrum beta-lactamases. Antimicrob Agents
Chemother 2005; 49: 4754–4756.
17. Paterson DL. Recommendation for treatment of severe
infections caused by Enterobacteriaceae producing exten-
ded-spectrum beta-lactamases (ESBLs). Clin Microbiol
Infect 2000; 6: 460–463.
RESEARCH NOTE
Development of high-level ceftazidime
resistance via single-base substitutions of
blaCTX-M-3 in hyper-mutable Escherichia coli
E. Karisik, M. J. Ellington, R. Pike,
D. M. Livermore and N. Woodford
Antibiotic Resistance Monitoring and Reference
Laboratory, Centre for Infections, Health Pro-
tection Agency, London, UK
ABSTRACT
Mutations can increase the ceftazidimase activity
of CTX-M-3 b-lactamase, as seen with its wide-
spread variant CTX-M-15. This study compared
the frequencies of emerging ceftazidime resist-
ance in isogenic wild-type and hyper-mutable
mutS CTX-M-3-producing Escherichia coli strains,
and sequenced the mutant blaCTX-M alleles selec-
ted. Ceftazidime resistance emerged more readily
in the hyper-mutable background than in the
wild-type strain. All selected CTX-M mutants, in
both the wild-type and the mutS derivatives, had
single amino-acid changes at position 167, inclu-
ding a novel Pro167Gln substitution. These data
emphasise the potential for further diversification
of CTX-M enzymes.
Keywords b-Lactamase, ceftazidime, CTX-M en-
zymes, Escherichia coli, resistance, selection
Original Submission: 27 October 2005; Revised Sub-
mission: 9 December 2005; Accepted: 10 January 2006
Clin Microbiol Infect 2006; 12: 803–806
10.1111/j.1469-0691.2006.01423.x
The extensive use of third-generation cephalospo-
rins seems likely to have played a major role in the
selection of CTX-M enzymes, with some sugges-
tions that cefepime and ceftriaxone may be par-
ticularly selective [1]. Most CTX-M enzymes have
weak catalytic activity against ceftazidime, but
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